We use cookies for a better user experience. Read our Privacy Policy

I Agree

Nanomedicine Market

Nanomedicine Market (Application: Cardiovascular, Anti-inflammatories, Anti-infectives, Neurology, Oncology, and Others [Dental, Orthopedic, Urology, and Ophthalmic]) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2021-2028

Nanomedicine Market Outlook 2028

  • The global nanomedicine market was valued at US$ 198.9 Bn in 2020
  • It is estimated to expand at a CAGR of 12.6% from 2021 to 2028
  • The global nanomedicine market is expected to reach the value of US$ 512.5 Bn by the end of 2028

Analysts’ Viewpoint on Nanomedicine Market Scenario

The significant presence of players in the global naomedicine market are gaining lucrative revenue opportunities. Large number of ongoing clinical trials, outsourcing services, research activities, and increasing healthcare investment by governments are some of the factors responsible for the expansion of the naomedicine market. Rise in prevalence of chronic diseases such as cancer and cardiovascular diseases is a major factor for the rising popularity of nanomedicines. In addition, rising geriatric population, increase in the number of patients with obesity, high blood pressure, and various other cardiovascular diseases are contributing to the growth of the nanomedicine market. However, high costs involved in research and manufacturing of nanomedicines as well as high cost of these drugs for consumers are some of the factors expected to hamper the growth of the global naomedicine market during the forecast period.

Rising Prevalence of Chronic Diseases to Boost Nanomedicine Market

Nanomedicine is widely used in the treatment of chronic diseases such as cardiovascular diseases, diabetes, cancer, dementia, and others, where it aids in the rapid metabolism of medications in the body. Hence, rise in prevalence of chronic diseases is expected to boost the growth of the global market. Although the fields of medicine and healthcare have undergone incredible developments in the past few decades, with the introduction of breakthrough products and therapies such as portable imaging devices, non-invasive surgical tools, and advanced medical sensors, there still remains a wide gap between patient needs and available treatments.

Advances in nanomedicine attempt at filling this gap. The promise of nanomedicines of delivering drugs at the target site in the right proportion and at the necessary rate of delivery will cater well to the needs of complicated disease conditions, significantly driving the global nanomedicines market. The market will also be significantly driven by the significant rise in the prevalence of chronic diseases across the globe.

Request a sample to get extensive insights into the Nanomedicine Market

Oncology a Lucrative Application Segment for Nanomedicine Market

The global naomedicine market is expected to witness tremendous growth opportunities due to rising incidences of oncology and chronic disorders across the globe. Due to rise in prevalence of cancer across the globe, nanomedicines plays an important role in the oncology segment. The vast rise in the number of cancer cases across the globe will continue to keep oncology one of the most lucrative application segments for nanomedicine over the forecast period as well. The nanomedicine market is significantly driven by factors such as increasing awareness among people about nanotechnology, rapidly increasing incidences of chronic illnesses, cancers, technological advancement, and rising investment in nanotechnology by government in several developing countries.

To understand how our report can bring difference to your business strategy, Ask for a brochure

Rise in Awareness of Benefits of Nanomedicines Drives Global Market

Due to rising demand for nanomedicines, manufacturers are gaining lucrative growth opportunities in the global market. Nanomedicine is an expanding area of the healthcare industry, and is witnessing increasing acceptance in medical and healthcare applications. The global nanomedicine market features a low concentration of technology and nanomaterial suppliers. To lessen the brunt of the inevitable demand-supply gap resulting, owing to the low number of suppliers, manufacturers in the market mostly depend on long-term contracts with pre-negotiated terms and conditions for uninterrupted supply of raw materials in domestic markets. The vast funds required to excel in the technology- and research-driven field of nanomedicine have kept new players at a bay. The nanomedicine market is witnessing rapid growth due to increase in research and development activities across the globe.

Stuck in a neck-to-neck competition with other brands? Request a custom report on Nanomedicine Market

Booming North America Nanomedicine Market

North America is expected to account for a major market share in the global nanomedicine market. Some of the major factors responsible for the market growth are well-established healthcare infrastructure and increasing number of biopharmaceutical companies in the region. The increasing prevalence chronic diseases all over the world demand for technologically advanced nanomedicines. The availability and adoption of nanomedical products such as nanorobots, DNA probes, monoclonal antibody-based immunoassays, nanosensors, and nanoparticle-based imaging agents are driving the market growth in nanomedicines. In addition, favorable regulatory environment is a key factor propelling the nanomedicine market in North America. Asia Pacific and Latin America are other attractive markets, which are poised to rise due to the increasing healthcare spending and improving healthcare facilities. This is due to economic growth, rise in spending capacity, surge in prevalence of cancers, and improvements in healthcare infrastructure.

Nanomedicine Market: Overview

  • According to Transparency Market Research’s latest report on the global nanomedicine market for the historical period 2017–2019 and forecast period from 2021 to 2028, increase in research funding, rise in government support, improved regulatory framework, technological advancements, and surge in prevalence of chronic diseases are projected to drive the global nanomedicine market during the forecast period

Rise in Prevalence of Chronic Diseases such as Cancer and Cardiovascular Diseases: Key Driver

  • Cancer is a leading cause of death across the world. According to the International Agency for Research on Cancer, the worldwide cancer burden has increased to 19.3 million cases and 10 million cancer deaths in 2020. By 2040, the number of new cancer cases per year is anticipated to reach 29.5 million, with 16.4 million cancer-related deaths.
  • Diet is one of the key risk factors that leads to increase in number of patients with obesity and high blood pressure. Hence, change in dietary habits results in rise in prevalence of cardiovascular diseases. According to the Centers for Disease Control and Prevention, heart diseases account for nearly 655,000 deaths in the U.S. each year.
  • Aging is consistently reported as a major risk factor for neurodegenerative diseases. Therefore, surge in geriatric population contributes to the increase in number of patients with various brain diseases. An article published in the Journal of the Alzheimer's Association indicated that the prevalence of Alzheimer’s dementia increases dramatically with age; 3% of people aged 65 to 74, 17% of people aged 75 to 84, and 32% of people aged 85 or older have Alzheimer’s dementia.
  • Nanomedicine is widely used in the treatment of chronic diseases such as cardiovascular diseases, diabetes, cancer, dementia, and others, where it aids in the rapid metabolism of medications in the body. Hence, rise in prevalence of chronic diseases is expected to boost the growth of the global market.

Improvement in Nanomedicine Technology Boosts Market Growth

  • Nanomedicine is a niche segment, with research & development as an integral part of the market. There is a need to identify and exploit the current technologies for nanomedicine such as nanocarriers, nanoparticles, and nanosensors to their full potential. Technologies such as targeted drug delivery, nanoparticle based diagnostic agents, and conjugated drug nanoparticles have already experienced an array of applications in the medical field.
  • Development of new technologies such as nanorobots, molecular nanotechnology (MNT), and nanovaccinology will open up new areas of applications and drive the nanomedicine market. The implications of lab-on-chip technology will be quite beneficial for the healthcare diagnostics market due to increased accuracy with reduced sampling size. Use of biomaterials in bone grafts and replacement therapies has improved the success rate and reduced complications in this segment. Hence, enhancement in the nanomedicine technology is expected to augment the market.

High Cost of Nanomedicine Manufacturing R&D to Hamper Market

  • The nanomedicine market is concerned about both research and manufacturing costs as well as market price for the end-user. For a developing organization, nanomedicine research & development requires a large amount of resources, which raises worries about receiving finances.
  • Research activities involving new technology development require significant investment, which is expected to be received with significant profits by the innovator. Nanomedicine is a niche segment and requires high investment. This deters companies to enter the market due to uncertainty of receiving expected profit.

Nanomedicine Market: Competition Landscape

  • This report profiles major players in the global nanomedicine market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments
  • The global nanomedicine market is quite competitive, with the top ten players accounting for major share of the market and companies focusing on research & development to produce better pharmaceutical and vaccine products for the existing diseases
  • Leading players operating in the global nanomedicine market are
    • Sigma-Tau Pharmaceuticals, Inc.
    • Celgene Corporation
    • Mallinckrodt plc
    • Teva Pharmaceutical Industries Ltd.
    • Johnson & Johnson
    • Merck & Co., Inc.
    • Pfizer, Inc.
    • GE Healthcare
    • UCB SA
    • Nanosphere, Inc.
    • CombiMatrix Corp
    • Abbott Laboratories, among others

Nanomedicine Market: Key Developments

  • Key players in the global nanomedicine market are engaged in regulatory approvals, technologically advanced products, launch of new products, and acquisition & collaborative agreements with other companies. These strategies are likely to fuel the growth of the global nanomedicine market. A few expansion strategies adopted by players operating in the global nanomedicine market are:
    • In January 2022, NaNotics LLC announced a research cooperation with Mayo Clinic in order to create a NaNot that targets the soluble version of PD-L1, a tumor-generated immune inhibitor
    • In August 2020, Innovasis, Inc. obtained the U.S. FDA authorization and released 3D-printed implants used in spinal fusion surgery. Moreover, Promimic's HAnano Surface Technology is used in these implants, which is a bioactive nano treatment for implant device surfaces that results in enhanced molecular anchoring of medical implants.
    • In April 2019, Nanobiotix, a clinical-stage nanomedicine company, received CE approval for Hensify (NBTXR3), an aqueous suspension of crystalline hafnium oxide (HfO2) nanoparticles designed for injection directly into the tumor prior to a patient's first standard radiotherapy treatment of metastatic soft tissue sarcoma.
  • The report on the global nanomedicine market discussed individual strategies, followed by company profiles of manufacturers of nanomedicine devices. The competitive landscape section has been included in the report to provide readers with a dashboard view and a company market share analysis of key players operating in the global nanomedicine market.

Nanomedicine Market Snapshot

Attribute

Detail

Market Size Value in 2020

US$ 198.9 Bn

Market Forecast Value in 2028

US$ 512.5 Bn

Growth Rate (CAGR)

12.6%

Forecast Period

2021–2028

Quantitative Units

US$ Mn for Value

Market Analysis

It includes cross segment analysis at global as well as regional level. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, and parent industry overview.

Competition Landscape

  • Market share analysis by company (2020)
  • Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials

Format

Electronic (PDF) + Excel

Market Segmentation

  • By Application
    • Cardiovascular
    • Anti-inflammatories
    • Anti-infectives
    • Neurology
    • Oncology
    • Others

Regions Covered

  • North America
  • Latin America
  • Europe
  • Latin America
  • Middle East & Africa

Countries Covered

  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • China
  • India
  • Japan
  • Australia & New Zealand
  • Brazil
  • Mexico
  • GCC Countries
  • South Africa

Companies Profiled

  • GE Healthcare
  • Merck & Co, Inc.
  • Abbott Laboratories
  • Pfizer, Inc.
  • Nanosphere, Inc.
  • Mallinckrodt plc,
  • Teva Pharmaceutical Industries Ltd.
  • Sigma-Tau Pharmaceuticals, Inc.
  • Celgene Corporation
  • Novavax, Inc.
  • Life Technologies
  • MagArray, Inc.
  • Gilead Sciences, Inc.
  • Other prominent players

Customization Scope

Available upon request

Pricing

Available upon request

Nanomedicine Market – Segmentation

Application
  • Cardiovascular
  • Anti-inflammatory
  • Anti-infectives
  • Neurology
  • Oncology
  • Others (Dental, Orthopedic, Urology, and Ophthalmic)
Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Interested in this report?
Get a FREE sample now!

Get Free Sample

*Get Sample Report (PDF) sent to your email within minutes

Frequently Asked Questions

What is the total market worth of nanomedicine market?

The global nanomedicine market was worth US$ 198.9 Bn and is projected to reach a value of US$ 512.5 Bn by the end of 2028

What is the anticipated CAGR of the nanomedicine market in the forecast period?

Nanomedicine market is anticipated to grow at a CAGR of 12.6% during the forecast period

Which region is expected to project the highest market share in the global nanomedicine market?

North America accounted for a major share of the global nanomedicine market

What are the key driving factors for the growth of the nanomedicine market?

Nanomedicine market is driven by rise in prevalence of chronic diseases such as cardiovascular diseases, diabetes, and cancer is expected to drive the demand for nanomedicines in the next few years

Who are the key players in the global nanomedicine market?

Key players in the global nanomedicine market include GE Healthcare, Merck & Co, Inc., Abbott Laboratories, Pfizer, Inc., Nanosphere, Inc., Mallinckrodt plc, Teva Pharmaceutical Industries Ltd., Sigma-Tau Pharmaceuticals, Inc., Celgene Corporation, Novavax, Inc., Life Technologies, MagArray, Inc., and Gilead Sciences, Inc.

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Nanomedicine Market

4. Market Overview

    4.1. Introduction

        4.1.1. Definition

        4.1.2. Industry Evolution / Developments

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities

    4.4. Global Nanomedicine Market Analysis and Forecast, 2017–2028

5. Key Insights

    5.1. Technological Advancements

    5.2. Key Mergers & Acquisitions

    5.3. Regulatory Scenario by Region/globally

    5.4. COVID-19 Pandemics Impact on Industry

6. Global Nanomedicine Market Analysis and Forecast, by Application

    6.1. Introduction & Definition

    6.2. Key Findings / Developments

    6.3. Market Value Forecast, by Application, 2017–2028

        6.3.1. Cardiovascular

        6.3.2. Anti-inflammatories

        6.3.3. Anti-invectives

        6.3.4. Neurology

        6.3.5. Oncology

        6.3.6. Others

    6.4. Market Attractiveness Analysis, by Application

7. Global Nanomedicine Market Analysis and Forecast, by Region

    7.1. Key Findings

    7.2. Market Value Forecast, by Region

        7.2.1. North America

        7.2.2. Europe

        7.2.3. Asia Pacific

        7.2.4. Latin America

        7.2.5. Middle East & Africa

    7.3. Market Attractiveness Analysis, by Region

8. North America Nanomedicine Market Analysis and Forecast

    8.1. Introduction

        8.1.1. Key Findings

    8.2. Market Value Forecast, by Application, 2017–2028

        8.2.1. Cardiovascular

        8.2.2. Anti-inflammatories

        8.2.3. Anti-infective

        8.2.4. Neurology

        8.2.5. Oncology

        8.2.6. Others

    8.3. Market Value Forecast, by Country, 2017–2028

        8.3.1. U.S.

        8.3.2. Canada

    8.4. Market Attractiveness Analysis

        8.4.1. By Application

        8.4.2. By Country

9. Europe Nanomedicine Market Analysis and Forecast

    9.1. Introduction

        9.1.1. Key Findings

    9.2. Market Value Forecast, by Application, 2017–2028

        9.2.1. Cardiovascular

        9.2.2. Anti-inflammatories

        9.2.3. Cardiovascular

        9.2.4. Neurology

        9.2.5. Oncology

        9.2.6. Others

    9.3. Market Value Forecast, by Country/Sub-region, 2017–2028

        9.3.1. Germany

        9.3.2. U.K.

        9.3.3. France

        9.3.4. Italy

        9.3.5. Spain

        9.3.6. Rest of Europe

    9.4. Market Attractiveness Analysis

        9.4.1. By Application

        9.4.2. By Country/Sub-region

10. Asia Pacific Nanomedicine Market Analysis and Forecast

    10.1. Introduction

        10.1.1. Key Findings

    10.2. Market Value Forecast, by Application, 2017–2028

        10.2.1. Cardiovascular

        10.2.2. Anti-inflammatories

        10.2.3. Anti-infective

        10.2.4. Neurology

        10.2.5. Oncology

        10.2.6. Others

    10.3. Market Value Forecast, by Country/Sub-region, 2017–2028

        10.3.1. China

        10.3.2. Japan

        10.3.3. India

        10.3.4. Australia & New Zealand

        10.3.5. Rest of Asia Pacific

    10.4. Market Attractiveness Analysis

        10.4.1. By Application

        10.4.2. By Country/Sub-region

11. Latin America Nanomedicine Market Analysis and Forecast

    11.1. Introduction

        11.1.1. Key Findings

    11.2. Market Value Forecast, by Application, 2017–2028

        11.2.1. Cardiovascular

        11.2.2. Anti-inflammatories

        11.2.3. Anti-infectives

        11.2.4. Neurology

        11.2.5. Oncology

        11.2.6. Others

    11.3. Market Value Forecast, by Country/Sub-region, 2017–2028

        11.3.1. Brazil

        11.3.2. Mexico

        11.3.3. Rest of Latin America

    11.4. Market Attractiveness Analysis

        11.4.1. By Application

        11.4.2. By Country/Sub-region

12. Middle East & Africa Nanomedicine Market Analysis and Forecast

    12.1. Introduction

        12.1.1. Key Findings

    12.2. Market Value Forecast, by Application, 2017–2028

        12.2.1. Cardiovascular

        12.2.2. Anti-inflammatories

        12.2.3. Anti-infectives

        12.2.4. Neurology

        12.2.5. Oncology

        12.2.6. Others

    12.3. Market Value Forecast, by Country/Sub-region, 2017–2028

        12.3.1. GCC Countries

        12.3.2. South Africa

        12.3.3. Rest of Middle East & Africa

    12.4. Market Attractiveness Analysis

        12.4.1. By Application

        12.4.2. By Country/Sub-region

13. Competition Landscape

    13.1. Market Player - Competition Matrix (by tier and size of companies)

    13.2. Market Share Analysis, by Company, 2020

    13.3. Company Profiles

        13.3.1. Abbott Laboratories

            13.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

            13.3.1.2. Financial Analysis

            13.3.1.3. Growth Strategies

            13.3.1.4. SWOT Analysis

        13.3.2. CombiMatrix Corporation

            13.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

            13.3.2.2. Financial Analysis

            13.3.2.3. Growth Strategies

            13.3.2.4. SWOT Analysis

        13.3.3. Celgene Corporation

            13.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

            13.3.3.2. Financial Analysis

            13.3.3.3. Growth Strategies

            13.3.3.4. SWOT Analysis

        13.3.4. GE Healthcare

            13.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)

            13.3.4.2. Financial Analysis

            13.3.4.3. Growth Strategies

            13.3.4.4. SWOT Analysis

        13.3.5. Johnson & Johnson

            13.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

            13.3.5.2. Financial Analysis

            13.3.5.3. Growth Strategies

            13.3.5.4. SWOT Analysis

        13.3.6. Mallinckrodt plc

            13.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)

            13.3.6.2. Financial Analysis

            13.3.6.3. Growth Strategies

            13.3.6.4. SWOT Analysis

        13.3.7. Merck & Company Inc.

            13.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)

            13.3.7.2. Financial Analysis

            13.3.7.3. Growth Strategies

            13.3.7.4. SWOT Analysis

        13.3.8. Nanosphere, Inc.

            13.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)

            13.3.8.2. Financial Analysis

            13.3.8.3. Growth Strategies

            13.3.8.4. SWOT Analysis

        13.3.9. Pfizer Inc.

            13.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)

            13.3.9.2. Financial Analysis

            13.3.9.3. Growth Strategies

            13.3.9.4. SWOT Analysis

        13.3.10. Sigma-Tau Pharmaceuticals Inc.

            13.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)

            13.3.10.2. Financial Analysis

            13.3.10.3. Growth Strategies

            13.3.10.4. SWOT Analysis

        13.3.11. Teva Pharmaceutical Industries Ltd

            13.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)

            13.3.11.2. Financial Analysis

            13.3.11.3. Growth Strategies

            13.3.11.4. SWOT Analysis

        13.3.12. UCB S.A.

            13.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)

            13.3.12.2. Financial Analysis

            13.3.12.3. Growth Strategies

            13.3.12.4. SWOT Analysis

List of Tables

Table 01: Global Nanomedicine Market Value (US$ Mn) Forecast, by Application, 2017–2028

Table 02: Global Nanomedicine Market Value (US$ Mn) Forecast, by Region, 2017–2028

Table 03: North America Nanomedicine Market Value (US$ Mn) Forecast, by Country, 2017–2028

Table 04: North America Nanomedicine Market Value (US$ Mn) Forecast, by Application, 2017–2028

Table 05: Europe Nanomedicine Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2028

Table 06: Europe Nanomedicine Market Value (US$ Mn) Forecast, by Application, 2017–2028

Table 07: Asia Pacific Nanomedicine Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2028

Table 08: Asia Pacific Nanomedicine Market Value (US$ Mn) Forecast, by Application, 2017–2028

Table 09: Latin America Nanomedicine Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2028

Table 10: Latin America Nanomedicine Market Value (US$ Mn) Forecast, by Application, 2017–2028

Table 11: Middle East & Africa Nanomedicine Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2028

Table 12: Middle East & Africa Nanomedicine Market Value (US$ Mn) Forecast, by Application, 2017–2028

List of Figures

Figure 01: Global Nanomedicine Market Value Share Analysis, by Application, 2021 and 2028

Figure 02: Global Nanomedicine Market Attractiveness Analysis, by Application, 2021–2028

Figure 03: North America Nanomedicine Market Value (US$ Mn) Forecast, 2017–2028

Figure 04: North America Nanomedicine Market Value Share Analysis, by Country, 2021 and 2028

Figure 05: North America Nanomedicine Market Attractiveness Analysis, by Country, 2021–2028

Figure 06: North America Nanomedicine Market Value Share Analysis, by Application, 2021 and 2028

Figure 07: North America Nanomedicine Market Attractiveness Analysis, by Application, 2021–2028

Figure 08: Europe Nanomedicine Market Value (US$ Mn) Forecast, 2017–2028

Figure 09: Europe Nanomedicine Market Value Share Analysis, by Country/Sub-region, 2021 and 2028

Figure 10: Europe Nanomedicine Market Attractiveness Analysis, by Country/Sub-region, 2021–2028

Figure 11: Europe Nanomedicine Market Value Share Analysis, by Application, 2021 and 2028

Figure 12: Europe Nanomedicine Market Attractiveness Analysis, by Application, 2021–2028

Figure 13: Asia Pacific Nanomedicine Market Value (US$ Mn) Forecast, 2017–2028

Figure 14: Asia Pacific Nanomedicine Market Value Share Analysis, by Country/Sub-region, 2021 and 2028

Figure 15: Asia Pacific Nanomedicine Market Attractiveness Analysis, by Country/Sub-region, 2021–2028

Figure 16: Asia Pacific Nanomedicine Market Value Share Analysis, by Application, 2021 and 2028

Figure 17: Asia Pacific Nanomedicine Market Attractiveness Analysis, by Application, 2021–2028

Figure 18: Latin America Nanomedicine Market Value Share Analysis, by Country/Sub-region, 2021 and 2028

Figure 19: Latin America Nanomedicine Market Attractiveness Analysis, by Country/Sub-region, 2021–2028

Figure 20: Latin America Nanomedicine Market Attractiveness Analysis, by Application, 2021–2028

Figure 21: Middle East & Africa Nanomedicine Market Value Share Analysis, by Country/Sub-region, 2021 and 2028

Figure 22: Middle East & Africa Nanomedicine Market Attractiveness Analysis, by Country/Sub-region, 2021–2028

Figure 23: Middle East & Africa Nanomedicine Market Attractiveness Analysis, by Application, 2021–2028

Transparency Market Research Plus

Get a free copy if the report you purchased is updated within 90 days

Copyright © Transparency Market Research, Inc. All Rights reserved